Aspirin Could Limit Effectiveness of New Heart Drug

Aspirin Could Limit Effectiveness of New Heart DrugA new analysis could shed light on why high doses of aspirin have limited the effectiveness of AstraZeneca's new heart drug Brilinta, which has already been approved in 33 countries around the world.

According to Reuters, the drugmaker hit a snag when seeking approval for the medication in the U.S. after a study showed less-than-stellar results for patients in North America. The clinical trial reportedly suggested that Brilinta was not as effective as Plavix, which is a rival medication, according to the news source.

However, experts are now focusing on the possibility that high doses of aspirin could hinder the effects of Brilinta, particularly as patients are generally prescribed higher doses of aspirin with heart drugs in the U.S. than they are in Europe.

The latest analysis, which was published recently in the medical journal Circulation, indicated that while the varying regions could play a role themselves, reportedly seemed to support the claim that aspirin limited Brilinta's effectiveness, according to the news source.

According to The Wall Street Journal, the U.S. Food and Drug Administration opted to delay approval of the medication last December.